BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

If we take a look at Pfizer’s top products for 2024, we can observe that the sales from their COVID vaccine, Comirnaty, dropped more than 50% vs. 2023 due to a decrease in vaccinations globally ...

Pharmaceutical giant Pfizer recently shared its plans to revive vaccine awareness in Mexico and become a key vaccine supplier ...

Pfizer Inc. (NYSE: PFE) was one of these and dropped out of the strategy before the COVID-19 vaccine. PFE is worse than out-of-favor but still pays one of the highest dividends among DOW components.

In an exclusive interview, Sally Susman, a pioneer in corporate comms, recounts finding out that Pfizer's COVID-19 vaccine was viable.

Pfizer (PFE) announced it does not anticipate significant changes to U.S. vaccine policy under the incoming Trump administration, despite vaccine skeptic Robert F. Kennedy Jr.’s nomination to ...

With a market cap of $145.7 billion, Pfizer Inc. (PFE) is a global, research-driven biopharmaceutical company, specializing in the discovery, development, and commercialization of innovative medicines ...

Pfizer’s news about the effectiveness of its Covid-19 vaccine came nearly a week after Election Day, but Pfizer CEO Albert Bourla has said the timing had nothing to do with politics.

The settlements will see BioNTech pay $791.5 million to NIH and $467 million to Penn, with Pfizer (PFE), its vaccine partner, reimbursing part of these payments.